文献速递胸部肿瘤

免疫标志物定义的大细胞肺癌中可操作分子改变的全景

The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.
PubMed 文献 · J Thorac Oncol · 2019-04-09

研究对789例切除的NSCLC进行回顾性分析,识别出59例缺乏形态学分化的NSCLC(占7.5%),按2015年WHO分类通过免疫组化重新分类为腺癌(LCC-AD,20例)、鳞癌(LCC-SqCC,14例)和LCC-Null(25例)。约92%的LCC-Null、95%的LCC-AD和86%的LCC-SqCC携带临床相关分子改变,LCC-Null组高表达PD-L1且细胞周期调控基因改变频率高,为靶向治疗提供了替代选择。

要点

  • 59例缺乏形态学分化的NSCLC中,33.9%重新分类为LCC-AD,23.7%为LCC-SqCC,42.4%为LCC-Null。
  • LCC-AD组检出腺癌特征性改变(EGFR、KRAS、ALK、ROS1、STK11),LCC-SqCC组检出鳞癌特征性改变(PIK3CA、SOX2、FGFR1、AKT1)。
  • LCC-Null组高表达PD-L1且细胞周期调控基因改变频率高,提供靶向治疗替代选择。

核心结论

  • 该综合分子研究进一步揭示了大细胞肺癌的遗传架构,多数肿瘤存在临床可操作改变,使个体化治疗成为可能。

研究设计与样本

  • 回顾性分析789例切除的NSCLC连续队列,识别出59例缺乏形态学分化的NSCLC(占7.5%),按2015年WHO肺肿瘤分类通过免疫组化重新分类,并采用靶向捕获测序、免疫组化和荧光原位杂交多技术检测分子改变。

主要发现

  • 59例缺乏形态学分化的NSCLC中,20例(33.9%)重新分类为腺癌(LCC-AD),14例(23.7%)为鳞状细胞癌(LCC-SqCC),25例(42.4%)为LCC-Null。
  • 约92%的LCC-Null、95%的LCC-AD和86%的LCC-SqCC携带临床相关改变。
  • 腺癌特征性改变(EGFR、KRAS、ALK、ROS1、STK11)在LCC-AD亚组检出,LCC-SqCC组未检出;鳞癌特征性改变(PIK3CA、SOX2、FGFR1、AKT1)在LCC-SqCC亚组检出,LCC-AD组未检出。
  • 部分LCC-Null肿瘤显示与腺癌或鳞癌相似的遗传谱,但超过一半的LCC-Null组完全缺乏可识别的谱系特异性遗传谱。
  • LCC-Null组高表达PD-L1且细胞周期调控基因改变频率高,提供靶向治疗替代选择。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients with pulmonary large-cell carcinoma (LCC) have poor prognosis and limited treatment options. The identification of clinically actionable molecular alterations helps to guide personalized cancer treatment decisions. PATIENTS AND METHODS: A consecutive cohort of 789 resected NSCLC cases were reviewed. Fifty-nine NSCLC cases lacking morphologic differentiation, accounting for 7.5% of all resected NSCLCs, were identified and further characterized by immunohistochemistry according to the 2015 WHO lung tumor classification. Molecular alterations were investigated by multiple technologies including target capture sequencing, immunohistochemistry, and fluorescence in situ hybridizations. RESULTS: Of 59 NSCLC cases lacking morphologic differentiation, 20 (33.9%) were reclassified as adenocarcinoma (LCC-AD), 14 (23.7%) as squamous cell carcinoma (LCC-SqCC), and 25 (42.4%) as LCC-Null. Approximately 92% of LCC-Null, 95% of LCC-AD, and 86% of LCC-SqCC harbored clinically relevant alterations. Alterations characteristic of adenocarcinoma (EGFR, KRAS, ALK receptor tyrosine kinase [ALK], ROS1, and serine/threonine kinase 11 [STK11]) were detected in the LCC-AD subgroup but not in LCC-SqCC, whereas squamous-lineage alterations (phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit alpha [PIK3CA], SRY-box 2 [SOX2], fibroblast growth factor receptor 1 [FGFR1], and AKT1) were detected in the LCC-SqCC subgroup but not in the LCC-AD group. Although some LCC-Null tumors displayed a genetic profile similar to either adenocarcinoma or squamous-cell carcinoma, more than half of the LCC-Null group were completely devoid of recognizable lineage-specific genetic profiles. High programmed death ligand 1 expression and high frequency of cell cycle regulatory gene alterations were found in the LCC-Null group offering alternative options of targeted therapy. CONCLUSIONS: This comprehensive molecular study provided further insight into the genetic architecture of LCC. The presence of clinically actionable alterations in a majority of the tumors allowed personalized treatment to emerge.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Chan AW, Chau SL, Tong JH, et al. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung. J Thorac Oncol. 2019. PMID: 30978501. doi:10.1016/j.jtho.2019.03.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。